i-Pharm GxP

Recent research has shown promising results for a novel gene therapy that targets chronic kidney disease by reducing the accumulation of damaging proteins, particularly in models of kidney disease where traditional treatments are limited. 🧬 The gene therapy, tested on mice, effectively decreased levels of harmful proteins involved in the progression of kidney disease, demonstrating the potential to slow down or halt the deterioration of kidney function. The research showed successful gene therapy administration in both small animal models and pigs, highlighting its scalability for human use. By targeting the root causes of protein overproduction that lead to kidney inflammation and fibrosis, this approach could make gene therapy a groundbreaking option in treating kidney disease. ___________ How do you see this advancement in gene therapy shaping the way we treat kidney disease in future? Leave your thoughts in the comments below. 🤔 #iPharmGxP #genetherapy #cellandgene

Last week, we asked for your opinions on the emerging trends in digital health funding as we look towards Q4 2024. 📊 Our poll results showed a clear preference, with 67% of you highlighting an increased focus on AI/ML as the biggest trend, while 33% went for a surge in partnerships and M&A. This shift towards AI and machine learning suggests a transformative period ahead in digital health. ________________ Leave your thoughts on these results in the comment section below! 💭 #digitalhealth #AI #iPharmGxP

At i-Pharm GxP, we have three key focusses that keep us moving forward: 1️⃣ Smart Connections: We’re all about finding and keeping the best people in the industry, helping them grow and thrive. 2️⃣ Creative Solutions: Every project gets a tailored approach so we can deliver real value and results that make a difference. 3️⃣ Collaborative Partnerships: We work closely with our partners, solving challenges together and aiming to make a lasting impact. ___________ Want to know more about how we do it? Check us out: https://lnkd.in/dS9x-f6K #iPharmGxP #lifesciences #talentsolutions

🚨 The World Health Organization has declared monkeypox a global health emergency again. Vaccine production is ramping up, with millions of doses expected by 2025. While a vaccine exists, more data is needed on its effectiveness, especially for vulnerable groups like children. Meanwhile, researchers are making progress toward a schistosomiasis vaccine by studying rhesus macaques, which naturally fight off the infection. Early trials are promising, bringing the industry closer to breaking the cycle of this neglected disease. _______________ What do you think about these vaccine developments? Share your thoughts below. ⬇️ #monkeypox #vaccination #iPharmGxP

In Q3 of 2024, we saw U.S. digital health startups secure $2.4 billion in venture capital across 110 deals. While the number of deals decreased from the previous quarter, the focus on larger, high-impact investments remained strong. As we enter the final quarter of 2024, it's clear that the landscape is evolving. Investors are leaning into "fewer, more focused bets" on promising innovations. But what’s next? 🤔 __________________ Vote in the poll below and leave your thoughts in the comments section! 📊 #digitalhealth #Q42024 #iPharmGxP

In Q3 of 2024, U.S. digital health startups attracted $2.4 billion in venture capital across 110 deals. While this marks a drop in the number of deals from the previous quarter (133 deals in Q2), the average deal size remained steady at $22 million. This shift signals a strategic change in the funding landscape, with investors making "fewer, more focused bets" on high-potential startups. This targeted approach speaks to the importance of quality over quantity, especially as medical device technologies continue to evolve. _____________ What trends do you think we will see in the industry as we head into the last quarter of 2024? Leave your thoughts in the comments below! ⬇️ #medicaldevices #iPharmGxP #Q32024

i-Pharm GxP's first year is complete! 🎉 It’s been a year of hard work and strong partnerships and we want to thank our committed team and valued clients for helping us achieve great results. From sterile manufacturing to biologics, quality assurance and everything in between, we've collaborated across a range of projects to deliver high-quality solutions and ensure compliance. As we continue to expand our capabilities and expertise, we're look forward to the next year of tackling new challenges and achieving our goals. Our mission remains clear: to ensure patient access to life-saving therapeutics through human-centric partnerships, projects, and solutions. #anniversary #lifesciences #iPharmGxP

A recent $105 million funding round is set to propel innovative gene therapies for chronic kidney disease into the clinic. 🧬 With approximately 840 million people affected globally, this breakthrough has the potential to have a huge impact on our industry. The funding will support a Phase 1/2 trial for a novel treatment targeting IgA nephropathy, a condition that often leads to kidney failure. This pioneering approach utilises gene therapy to restore vital kidney function, paving the way for future clinical applications. ___________ How do you think this breakthrough could shape the future of kidney disease treatment? Leave your thoughts in the comments below. 👇 #lifesciences #kidneydisease #genetherapy #iPharmGxP

Tune in to Episode 6 of the #GxPodcast! 🎧 We had the privilege of speaking with Eckart W Schwarz, MD, President and Founder of a bespoke Life Science Consultancy. Eckart has designed and delivered global strategic and operational solutions in the life sciences sector. His impressive career includes spearheading groundbreaking initiatives at GSK. Join us as we dive into insightful conversations about the globalisation of drug treatment, tech breakthroughs, biopharmaceutical advancements and much more! Listen now: 🎙️ https://lnkd.in/e2wRUhfF #iPharmGxP #LifeSciences #Pharmaceuticals #DrugDevelopment

It's been a while since we've come on here to look at our markets and talk about the work we do within them. 🕣 At i-Pharm GXP, our team of expert consultants partners with clients across three key sectors within global life sciences: 💉 Sterile / Aseptic Manufacturing 🧬 Biologics / Cell & Gene Therapy 🖥️ Medical Devices & Combination Products Explore the slides below to learn more about each of these specialised areas. 🔎 If you have a project in mind and would like to discuss further, reach out to our team or visit our website: 🔗 https://lnkd.in/dS9x-f6K #biologics #medicaldevices #iPharmGxP